RS55532B1 - Modulatori jetrenog x receptora - Google Patents
Modulatori jetrenog x receptoraInfo
- Publication number
- RS55532B1 RS55532B1 RS20161114A RSP20161114A RS55532B1 RS 55532 B1 RS55532 B1 RS 55532B1 RS 20161114 A RS20161114 A RS 20161114A RS P20161114 A RSP20161114 A RS P20161114A RS 55532 B1 RS55532 B1 RS 55532B1
- Authority
- RS
- Serbia
- Prior art keywords
- liver
- receptor modulators
- modulators
- receptor
- Prior art date
Links
- 102000004311 liver X receptors Human genes 0.000 title 1
- 108090000865 liver X receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612063P | 2012-03-16 | 2012-03-16 | |
| PCT/US2013/031250 WO2013138568A1 (en) | 2012-03-16 | 2013-03-14 | Liver x reception modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55532B1 true RS55532B1 (sr) | 2017-05-31 |
Family
ID=47997958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20161114A RS55532B1 (sr) | 2012-03-16 | 2013-03-14 | Modulatori jetrenog x receptora |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9073931B2 (sr) |
| EP (1) | EP2825542B1 (sr) |
| JP (3) | JP6114815B2 (sr) |
| KR (1) | KR102069913B1 (sr) |
| CN (1) | CN104203950B (sr) |
| AU (1) | AU2013232069B2 (sr) |
| BR (1) | BR112014022780A8 (sr) |
| CA (1) | CA2865639C (sr) |
| CY (1) | CY1118323T1 (sr) |
| DK (1) | DK2825542T3 (sr) |
| EA (1) | EA026431B1 (sr) |
| ES (1) | ES2607113T3 (sr) |
| HK (1) | HK1206332A1 (sr) |
| HR (1) | HRP20161690T1 (sr) |
| HU (1) | HUE030785T2 (sr) |
| IL (2) | IL234301A (sr) |
| LT (1) | LT2825542T (sr) |
| ME (1) | ME02660B (sr) |
| MX (1) | MX354820B (sr) |
| NZ (1) | NZ629189A (sr) |
| PL (1) | PL2825542T3 (sr) |
| PT (1) | PT2825542T (sr) |
| RS (1) | RS55532B1 (sr) |
| SG (1) | SG11201405323YA (sr) |
| SI (1) | SI2825542T1 (sr) |
| SM (1) | SMT201700009B (sr) |
| WO (1) | WO2013138568A1 (sr) |
| ZA (1) | ZA201406390B (sr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2825542T1 (sl) * | 2012-03-16 | 2017-01-31 | Vitae Pharmaceutical Inc., | Modulatorji jetrnega receptorja X |
| PL2825541T3 (pl) * | 2012-03-16 | 2016-12-30 | Modulatory receptora x wątroby | |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| WO2015195922A1 (en) * | 2014-06-19 | 2015-12-23 | Vitae Pharmaceuticals, Inc. | Compounds for use in treating acute coronary syndrome and related conditions |
| JP6605583B2 (ja) * | 2014-08-07 | 2019-11-13 | ヴァイティー ファーマシューティカルズ，エルエルシー | 肝臓ｘ受容体モジュレーターとしてのピペラジン誘導体 |
| WO2017083216A1 (en) * | 2015-11-12 | 2017-05-18 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
| AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3490579A1 (en) | 2016-07-27 | 2019-06-05 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
| WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| SG11202010115RA (en) | 2018-05-15 | 2020-11-27 | Alkahest Inc | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
| JP2022523773A (ja) * | 2019-02-28 | 2022-04-26 | ザ ロックフェラー ユニバーシティー | がんの予後及び治療におけるａｐｏｅ遺伝子型決定 |
| WO2021009664A1 (en) | 2019-07-15 | 2021-01-21 | Novartis Ag | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
| CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748247A (en) | 1986-10-21 | 1988-05-31 | American Home Products Corporation | 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists |
| US5356862A (en) | 1990-01-22 | 1994-10-18 | E. I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
| EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| CA2179650C (en) | 1993-12-23 | 2007-10-30 | William Francis Heath, Jr. | Bisindolemaleimides and their use as protein kinase c inhibitors |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| AU3831495A (en) | 1994-10-20 | 1996-05-15 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
| WO1998000134A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| AU719102B2 (en) | 1996-06-28 | 2000-05-04 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| JP2000514427A (ja) | 1996-06-28 | 2000-10-31 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプター拮抗薬プロドラッグ |
| US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
| FR2761070B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| FR2761073B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique |
| DE19802235A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Mit tricyclischen Indolen substituierte Oxazolidinone |
| ID23219A (id) | 1998-04-17 | 2000-03-30 | Lilly Co Eli | Trisiklik tersubstitusi |
| CA2371472A1 (en) | 1999-05-06 | 2000-11-16 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
| US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| IT1313593B1 (it) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo. |
| WO2001030331A2 (en) | 1999-10-22 | 2001-05-03 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| AU779855B2 (en) | 2000-01-06 | 2005-02-17 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
| AU8395501A (en) | 2000-07-31 | 2002-02-13 | Hoffmann La Roche | Piperazine derivatives |
| EP1343768A1 (en) | 2000-12-20 | 2003-09-17 | Bristol-Myers Squibb Pharma Company | Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| FR2829766A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives d'oxamates comportant un heterocycle azote diversement substitue |
| US7094895B2 (en) | 2001-12-21 | 2006-08-22 | King Pharmaceuticals Research & Development, Inc. | Tyrosyl derivatives and their use as P2X7 receptor modulators |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| DE10320780A1 (de) | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| JP4734119B2 (ja) | 2004-02-12 | 2011-07-27 | 田辺三菱製薬株式会社 | インダゾール化合物及びその医薬用途 |
| JP2007532506A (ja) | 2004-04-08 | 2007-11-15 | ノバルティス アクチエンゲゼルシャフト | 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤 |
| RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005113526A2 (en) | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one |
| AU2005315914B2 (en) * | 2004-12-15 | 2011-03-03 | F. Hoffmann-La Roche Ag | Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GlyT-1) inhibitors for the treatment of Alzheimer's disease |
| NZ555491A (en) | 2005-01-03 | 2010-01-29 | Univ Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| BRPI0612988A2 (pt) | 2005-07-14 | 2010-12-14 | Hoffmann La Roche | derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a |
| WO2007035841A1 (en) | 2005-09-21 | 2007-03-29 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| JP4882127B2 (ja) * | 2005-11-16 | 2012-02-22 | 株式会社ジェイテクト | 位置調整式ステアリング装置 |
| JP2007137810A (ja) * | 2005-11-17 | 2007-06-07 | Sankyo Co Ltd | インドール化合物を含有する医薬 |
| ATE448230T1 (de) | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| FR2897061B1 (fr) * | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| CN101679220A (zh) | 2007-04-09 | 2010-03-24 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| BRPI0813647A2 (pt) | 2007-06-25 | 2014-12-23 | Neurogen Corp | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados |
| US20100197657A1 (en) | 2007-09-25 | 2010-08-05 | Chang Ronald K | 2-aryl or heteroaryl indole derivatives |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| WO2009086129A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth | Pyrazolo [1,5-a] pyrimidine compounds |
| CL2009000116A1 (es) | 2008-01-22 | 2010-08-27 | Takeda Pharmaceutical Compnany Ltd | Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable. |
| WO2009097515A2 (en) | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| ES2588193T3 (es) | 2008-03-28 | 2016-10-31 | Nerviano Medical Sciences S.R.L. | Derivados de 3,4-dihidro-2H-pirazino[1,2-a]indol-1-ona activos como inhibidores de cinasa, proceso para su preparación y composiciones farmacéuticas que los comprenden |
| TW201031665A (en) | 2009-02-04 | 2010-09-01 | Gruenenthal Gmbh | Substituted indole-compound |
| BRPI1010649A2 (pt) | 2009-06-08 | 2016-06-07 | Gruenenthal Gmbh | benzimidazóis, benzotiazóis e benzoxazoles substituídos. |
| WO2011005295A1 (en) | 2009-06-24 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| MX2012002898A (es) | 2009-09-11 | 2012-04-02 | Sunovion Pharmaceuticals Inc | Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos. |
| EP2509979B1 (en) | 2009-12-07 | 2016-05-25 | Boehringer Ingelheim International GmbH | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| US20130045203A1 (en) | 2010-03-02 | 2013-02-21 | Emory University | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
| KR101302474B1 (ko) * | 2012-02-20 | 2013-09-02 | 주식회사 케이씨씨 | 내충격성 및 불연성이 우수한 진공단열재용 봉지부재 |
| SI2825542T1 (sl) * | 2012-03-16 | 2017-01-31 | Vitae Pharmaceutical Inc., | Modulatorji jetrnega receptorja X |
| PL2825541T3 (pl) * | 2012-03-16 | 2016-12-30 | Modulatory receptora x wątroby |
-
2013
- 2013-03-14 SI SI201330426A patent/SI2825542T1/sl unknown
- 2013-03-14 HU HUE13712103A patent/HUE030785T2/en unknown
- 2013-03-14 JP JP2015500603A patent/JP6114815B2/ja not_active Expired - Fee Related
- 2013-03-14 PL PL13712103T patent/PL2825542T3/pl unknown
- 2013-03-14 KR KR1020147028756A patent/KR102069913B1/ko active IP Right Grant
- 2013-03-14 EA EA201491610A patent/EA026431B1/ru unknown
- 2013-03-14 DK DK13712103.4T patent/DK2825542T3/en active
- 2013-03-14 MX MX2014011104A patent/MX354820B/es active IP Right Grant
- 2013-03-14 ME MEP-2016-289A patent/ME02660B/me unknown
- 2013-03-14 LT LTEP13712103.4T patent/LT2825542T/lt unknown
- 2013-03-14 BR BR112014022780A patent/BR112014022780A8/pt not_active Application Discontinuation
- 2013-03-14 US US14/385,671 patent/US9073931B2/en active Active
- 2013-03-14 RS RS20161114A patent/RS55532B1/sr unknown
- 2013-03-14 ES ES13712103.4T patent/ES2607113T3/es active Active
- 2013-03-14 WO PCT/US2013/031250 patent/WO2013138568A1/en active Application Filing
- 2013-03-14 SG SG11201405323YA patent/SG11201405323YA/en unknown
- 2013-03-14 NZ NZ629189A patent/NZ629189A/en not_active IP Right Cessation
- 2013-03-14 EP EP13712103.4A patent/EP2825542B1/en active Active
- 2013-03-14 CN CN201380014301.3A patent/CN104203950B/zh not_active Expired - Fee Related
- 2013-03-14 CA CA2865639A patent/CA2865639C/en not_active Expired - Fee Related
- 2013-03-14 PT PT137121034T patent/PT2825542T/pt unknown
- 2013-03-14 AU AU2013232069A patent/AU2013232069B2/en not_active Ceased
-
2014
- 2014-08-26 IL IL234301A patent/IL234301A/en active IP Right Grant
- 2014-08-29 ZA ZA201406390A patent/ZA201406390B/en unknown
-
2015
- 2015-05-26 US US14/721,262 patent/US9416135B2/en active Active
- 2015-07-16 HK HK15106802.8A patent/HK1206332A1/xx not_active IP Right Cessation
-
2016
- 2016-07-07 US US15/204,422 patent/US9707232B2/en active Active
- 2016-12-12 CY CY20161101280T patent/CY1118323T1/el unknown
- 2016-12-12 HR HRP20161690TT patent/HRP20161690T1/hr unknown
-
2017
- 2017-01-10 SM SM201700009T patent/SMT201700009B/it unknown
- 2017-03-14 JP JP2017048433A patent/JP2017128589A/ja active Pending
- 2017-04-25 IL IL251897A patent/IL251897A0/en unknown
- 2017-06-09 US US15/618,297 patent/US20180117041A1/en not_active Abandoned
-
2018
- 2018-09-14 JP JP2018172261A patent/JP2019006813A/ja active Pending
-
2019
- 2019-05-21 US US16/418,339 patent/US20200138812A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251897A0 (en) | X-receptor modulators of the liver | |
| GB201213700D0 (en) | Receptor antagnists II | |
| PL2663550T4 (pl) | Podstawione benzoazepiny jako modulatory receptora toll-podobnego | |
| EP2663555A4 (en) | SUBSTITUTED BENZOAZEPINES AS GREAT LIKE RECEPTOR MODULATORS | |
| HK1206333A1 (en) | Liver receptor modulators | |
| GB201004739D0 (en) | Receptor modulators | |
| HK1208867A1 (en) | Indolecarbonitriles as selective androgen receptor modulators | |
| HK1209744A1 (en) | Novel selective androgen receptor modulators | |
| IL235557A0 (en) | Modulators of 17 gpr receptors | |
| GB201223053D0 (en) | Receptor | |
| SI2820010T1 (sl) | Derivati benzofuran-2-sulfonamida kot modulatorji kemokinskih receptorjev | |
| EP2922539A4 (en) | SUBSTITUTED ISOQUINOLINES USEFUL AS MODULATORS OF THE CRTH2 RECEPTOR | |
| GB2501462B (en) | Structural fixing | |
| GB201202526D0 (en) | Structural fixing | |
| GB201219451D0 (en) | Tiling |